Simone Valeria, Rizzo Daniela, Cocciolo Alessandro, Caroleo Anna Maria, Carai Andrea, Mastronuzzi Angela, Tornesello Assunta
Pediatric Oncology Unit, Ospedale Vito Fazzi, Piazza Filippo Muratore, 1, 73100 Lecce, Italy.
Department of Onco-Hematology and Cell and Gene Therapy, Bambino Gesù Children's Hospital (IRCCS), Piazza Sant'Onofrio 4, 00146 Rome, Italy.
Diagnostics (Basel). 2021 Apr 8;11(4):670. doi: 10.3390/diagnostics11040670.
Brain tumors in infants including those diagnosed in fetal age, newborns and under a year old represent less than 10% of pediatric nervous system tumors and present differently when compared with older children in terms of clinical traits, location and histology. The most frequent clinical finding is a macrocephaly but non-specific symptoms can also be associated. The prognosis is usually poor and depends on several factors. Surgery continues to be the main option in terms of therapeutic strategies whereas the role of chemotherapy is not yet well defined and radiotherapy is exceptionally undertaken. In view of this situation, a molecular characterization could assist in providing therapeutic options for these tumors. This review highlights the recent advances in the diagnosis and treatment of brain tumors in infants with a particular focus on the molecular landscape and future clinical applications.
婴儿脑肿瘤,包括那些在胎儿期、新生儿期及1岁以下诊断出的脑肿瘤,占小儿神经系统肿瘤的比例不到10%,在临床特征、位置和组织学方面与大龄儿童相比表现不同。最常见的临床发现是巨头畸形,但也可能伴有非特异性症状。预后通常较差,取决于多种因素。在治疗策略方面,手术仍然是主要选择,而化疗的作用尚未明确界定,放疗则极少采用。鉴于这种情况,分子特征分析有助于为这些肿瘤提供治疗选择。本综述重点介绍了婴儿脑肿瘤诊断和治疗的最新进展,特别关注分子格局和未来的临床应用。